Overview

Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension

Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This study is an international, multicenter, open-label, long term extension study evaluating the safety of ecopipam tablets for the treatment of children and adolescent subjects with Tourette Syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
Emalex Biosciences Inc.
Treatments:
Ecopipam